Johnson & Johnson Acquires Israeli MedTech Startup in $1 Billion Purchase

Johnson & Johnson, the global pharmaceutical leader, has announced its acquisition of the Israeli medical startup V-Wave in a deal that could total up to $1.7 billion. This strategic move is set to enhance Johnson & Johnson MedTech’s offerings by integrating V-Wave’s cutting-edge Ventura Interatrial Shunt technology, which addresses heart failure with reduced ejection fraction (HFrEF).

V-Wave, founded in 2009 and based in Caesarea, Israel, has developed a novel implant designed to improve the lives of patients suffering from HFrEF—a condition where the heart struggles to pump blood effectively. This condition affects roughly 800,000 people in the U.S. annually, leading to significant health complications, frequent hospitalizations, and a high mortality rate.

The deal includes an upfront payment of $600 million, with the possibility of an additional $1.1 billion contingent on V-Wave achieving specific regulatory and commercial milestones. This acquisition underscores Johnson & Johnson’s commitment to advancing innovative medical technologies that address unmet needs in cardiovascular care.

V-Wave’s Ventura Interatrial Shunt is implanted using a minimally invasive catheter-based procedure. The device creates a shunt between the left and right atrium of the heart, helping to reduce elevated left atrial pressure—a key contributor to congestive heart failure. By mitigating this pressure, the device aims to lower the risk of cardiovascular events and reduce the number of hospitalizations for patients with heart failure.

The Ventura Interatrial Shunt has already received significant recognition, including FDA Breakthrough Device Designation in 2019 and CE mark approval in 2020, positioning it as a frontrunner in heart failure treatment. The device is particularly valuable as it bridges a critical gap between traditional medical therapies and more invasive procedures like left ventricular assist devices and heart transplants.

Dr. Neal Eigler, CEO of V-Wave, expressed optimism about the partnership. “We are confident that Johnson & Johnson MedTech is well-positioned to ensure V-Wave’s breakthrough ideas and technology reach patients in need as quickly and effectively as possible,” he said. “I couldn’t be prouder of the V-Wave team and the commitment it has taken to achieve this milestone. We look forward to continuing to build a world where cardiovascular disease is prevented, treated, and cured.”

This acquisition marks another significant step in Johnson & Johnson’s efforts to expand its cardiovascular treatment portfolio and bring innovative solutions to patients around the world.

Share this story to stay informed on the latest in medical innovation, and subscribe to our newsletter for more updates.